Chen S, et al. - In this investigation, researchers sought to characterize the features of irisin [a newly discovered hormone secreted by skeletal myocytes and fat tissue] in severe acute pancreatitis (SAP) [defined by the presence of local complications and/or transient or persistent organ failure and/or exacerbations of comorbidities]. From October 2016 to March 2018, the research selected 50 controls, 20 no acute pancreatitis (AP) patients, 20 AP, and 12 SAP patients. The outcomes exhibited no significant difference in the clinical parameters in all groups, except that in no AP, AP, and SAP white blood cells were significantly higher than the controls. Furthermore, irisin levels were significantly lower and maintained a steadily low trend in the SAP process compared to others, whereas in the SAP and AP groups, C-reactive protein, urine amylase and blood lipase were higher than others and continued to decrease. Findings suggested the possibility of the use of serum irisin as a novel biomarker linked to progression in SAP patients, particularly female SAP patients. Serum irisin can, therefore, be a useful index in SAP's clinical development and prognosis.